Earth Science Tech, Inc. Signs Agreement with TransBiotech to start in Vitro & in Vivo in Phase II for Nutraceutical Patents

Hollywood, Florida, UNITED STATES

Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) --  Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, is proud to announce the signing of an agreement with TransBiotech (, a member of Québec Innove (

TransBiotech will test the biological activity of the company’s new nutraceutical products in vitro, and then in vivo in a second stage. TransBiotech has vast expertise in analytic chemistry, which will help ETST pursue its goal of offering a stable product of very high quality.

The results the TransBiotech labs obtain from tests on formulas based on ETST’s International Provisional Patent Application will greatly help the acquisition of full patent protection for the company’s technology. The results will also support the development of these formulas into the creation of new prophylactic treatment for breast cancer and new treatment for other health issues such as metabolic or brain disorders, and Inflammatory Bowel Diseases.

TransBiotech can analyze and test ETST’s nutraceuticals and functional foods by employing chemistry analysis, based on the measurement of antioxidant capacity (ORAC), analysis of polyphenols, flavonoids, and fatty acid profiles (including omega-3, omega-6, EPA, DHA), amino acids, monosaccharides, and others.

This level of scientific scrutiny and expertise is exactly what the company needs to become a leader in its fields. For example, TransBiotech can help analyze the medicinal plants that will be used in ETST products by characterizing and quantifying the active ingredients.

This new partnership constitutes the second phase of the development of manufacturing processes for the three already-prototyped provisional CBD-based nutraceutical products that ETST has in the pipeline. The first phase was announced recently ( In this first phase, the company is working with CDBQ and TransBiotech’s world-renowned R&D groups to develop new ideas and products like those developed in the joint venture with Bionatus.

Updates on Joint Venture with the Canadian division of Brazilian company, Bionatus, for the creation of two natural medicines
In the next few days ETST will start working closely with Bionatus Pharmacognosique Laboratory Inc. As announced earlier (, the first goal of the joint venture is to improve Bionatus’ BioToss and Propovit medicinal products and introduce them into North American markets. Bionatus Pharmacognosique Laboratory Inc. has now an office at CQIB, a large research center in Laval, Québec, which will be used to develop new products.

André Konan, PhD, Manager, R&D and Regulatory Affairs - Bionatus Pharmacognosique Inc) said: “In addition to the joint improvement of BioToss and Propovit, we expect our partnership with ETST to stimulate the development of other strategic projects that will bring to market additional innovative plant-derived products, nutraceuticals, herbal medicines, hybrids, and drug substances.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. 

To learn more and to buy CBD Hemp Oil please visit:

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit:

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit:

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit:

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Contact Data